|
Gordon Parry, PhD, is Vice President of Research and Development, Oncology. Dr. Parry is responsible for the further development of Monogram’s proprietary VeraTag technology platform and the first product based on that platform the HERMark Breast Cancer Assay. Dr. Parry joined Monogram in 2007 as Senior Director of Research and Development, Oncology. Prior to joining Monogram, he worked for twelve years at Berlex Biosciences where he was the Department Head of their Cancer Research Department. Previously, he held a variety of research positions in academia, including ten years at the University of California’s Lawrence Berkeley Laboratory. He is currently an Advisory Council Member for the California Breast Cancer Research Program. Dr. Parry received his PhD in Biochemistry at the University of London.
| 